EHS
EHS

Treatment effect of apixaban consistent regardless of history of falls

Renato D. Lopes
In a subanalysis of the ARISTOTLE trial, history of falls had no bearing on the improved safety and efficacy of apixaban vs. warfarin in patients with nonvalvular atrial fibrillation, researchers reported.
Patients who had a history of falling had higher rates of bleeding and death compared with those who did not, but the benefits of apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) in reducing stroke and causing less bleeding than warfarin were consistent regardless of history of fall in the prior year, Renato D. Lopes, MD, PhD, MHS, professor of medicine in the division of
EHS
Back to top button